METHODS	In an open , randomized clinical trial conducted in pre-hemodialysis ( documented creatinine clearance < or = 30 mL/min ) and hemodialysis patients , over 15 years of age and nave for HB , the immunogenicity and safety of single doses of HB-AS04 ( Fendrix , GlaxoSmithKline Biologicals ) were compared to double doses of commercially available HB vaccine ( Engerix , GlaxoSmithKline Biologicals ) administered at 0 , 1 , 2 , and 6 months , and followed-up for 36 months .\